GOBIOLAB Signs Technology Transfer Agreement for Microbiome New Drug Candidate Worth 184 Billion KRW
[Asia Economy Reporter Geum Bo-ryeong] Gobiolab announced on the 30th that it has signed a technology transfer agreement for microbiome drug candidates KBL382 and KBL1027 with Kolmar Holdings.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The total contract amount is 184 billion KRW. Of this, approximately 181 billion KRW is milestone payments. These will be received in stages such as clinical phase, approval, and commercialization.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
